{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:12Z","timestamp":1761512772573},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Sir Charles Gairdner Hospital Foundation"},{"name":"Ciba-Geigy Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1996,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We have compared the use of new markers of bone turnover in the assessment and treatment of Paget disease and made observations on the mechanisms of bone resorption. Urine hydroxyproline (Hyp) as a bone resorption marker and serum alkaline phosphatase (ALP) as a bone formation marker have traditionally been used to biochemically assess and monitor treatment of Paget disease. Hyp and total ALP were compared with total urine pyridinoline (Pyd) and deoxypyridinoline (Dpd), free urine Pyd and Dpd, urine type I collagen N-terminal cross-linked telopeptide (NTX), type I collagen C-terminal propeptide (PICP), serum osteocalcin, and bone ALP in Paget patients treated with pamidronate. Patients were divided into three biochemical severity-based treatment groups by their fasting urine hydroxyproline excretion (HypE) levels (i.e., group 1, HypE &amp;lt; 5.0 \u03bcmol\/1 of glomerular filtrate [GF]; group 2, HypE of 5.0\u20139.9 \u03bcmol\/1 of GF; group 3, HypE &amp;lt; 10 \u03bcmol\/1 of GF). Group 1 received one 60 mg intravenous infusion of pamidronate, and groups 2 and 3 received four and six 60 mg infusions at weekly intervals, respectively. Fasting serum and morning urine specimens were taken before and at 2, 6, 13, and 26 weeks after starting treatment. Baseline Z scores were used to compare separation of patient results from normal, and the difference in Z scores from baseline to 13 weeks was used to compare response to treatment. Baseline discrimination and response to treatment at all disease activity levels was greatest for NTX and was poor for osteocalcin, PICP, and C-terminal cross-linked telopeptide of type I collagen (ICTP). The other markers showed good discrimination and response at medium and high levels of disease activity. NTX, total Pyd and Dpd, free Pyd and Dpd, and ICTP are all pyridinoline cross-link-based markers, but discrimination and response by NTX was generally much greater than for the others. Determination of the mechanism of the difference between NTX and other cross-link measures is necessary for appropriate use of the markers and may also lead to a better understanding of the bone resorption process. It has been proposed that the greater sensitivity and discrimination of NTX is because it is more bone-specific than the other cross-link markers with significant amounts of free Pyd and Dpd coming from nonbone sources. We propose another model where the proportion of peptide-bound cross-links such as NTX may be increased in high bone turnover states partly due to a rate-limiting step in their degradation to free cross-links. Conditions with high bone resorption rates would have high levels of NTX that would decline rapidly when resorption rates fall to a level where the capacity to degrade NTX matches the rate of production.<\/jats:p>","DOI":"10.1002\/jbmr.5650110817","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T15:37:04Z","timestamp":1265211424000},"page":"1176-1184","source":"Crossref","is-referenced-by-count":65,"title":["Comparison of biochemical markers of bone turnover in paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links"],"prefix":"10.1093","volume":"11","author":[{"given":"A.G.","family":"Mr. Randall","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, The Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.N.","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, The Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garcia-Webb","sequence":"additional","affiliation":[{"name":"St. John of God Pathology, Subiaco, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.I.","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, The Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, The Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Gutteridge","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Prince","sequence":"additional","affiliation":[{"name":"University Department of Medicine, QEII Medical Centre, Nedlands, Western Australia"},{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Fremantle Hospital, Fremantle, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Stuckey","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.K.","family":"Will","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Royal Perth Hospital, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.W.","family":"Retallack","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.I.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Medical Technology and Physics, QEII Medical Centre, Nedlands, Western Australia"},{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, QEII Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1996,8,1]]},"reference":[{"key":"2024013114245338800_bib1","doi-asserted-by":"crossref","first-page":"s549","DOI":"10.1002\/jbmr.5650081323","article-title":"Biochemical markers of bone turnover","volume":"8","author":"Delmas","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1043-2760(92)90129-O","article-title":"Urinary pyridinium crosslinks of collagen-specific markers of bone resorption in metabolic bone disease","volume":"3","author":"Seibel","year":"1992","journal-title":"Trends Endocrinol Metab"},{"key":"2024013114245338800_bib3","first-page":"590","volume-title":"Osteoporosis 1990","author":"Colwell","year":"1990"},{"key":"2024013114245338800_bib4","author":"Eyre","year":"1995"},{"key":"2024013114245338800_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/clinchem\/36.7.1328","article-title":"Radio-immunoassay for the carboxyterminal propeptide of human type I procollagen","volume":"36","author":"Melkko","year":"1990","journal-title":"Clin Chem"},{"key":"2024013114245338800_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/clinchem\/37.7.1143","article-title":"Bone protein and peptide assays in the diagnosis and management of skeletal disease","volume":"37","author":"Deftos","year":"1991","journal-title":"Clin Chem"},{"key":"2024013114245338800_bib7","first-page":"289","volume-title":"Biology and Physiology of the Osteoclast","author":"Delaise","year":"1992"},{"key":"2024013114245338800_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jbmr.5650090415","article-title":"Expression of 92kD type IV collagenase\/gelatinase B in human osteoclasts","volume":"9","author":"Wucherpfennig","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/1043-2760(93)90059-N","article-title":"Role of bisphosphonates in metabolic bone diseases","volume":"4","author":"Hamdy","year":"1993","journal-title":"Trends Endocrinol Metab"},{"key":"2024013114245338800_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.1991.tb00294.x","article-title":"Intravenous aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric, and radiological responses","volume":"34","author":"Fenton","year":"1991","journal-title":"Clin Endocrinol"},{"key":"2024013114245338800_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0003-2697(67)90160-1","article-title":"Modifications of a specific assay for hydroxyproline in urine","volume":"19","author":"Kivirikko","year":"1967","journal-title":"Anal Biochem"},{"key":"2024013114245338800_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0003-2697(88)90274-6","article-title":"Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography","volume":"169","author":"Black","year":"1988","journal-title":"Anal Biochem"},{"key":"2024013114245338800_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2362.1993.tb02034.x","article-title":"Factors affecting the assay of the urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption","volume":"23","author":"Colwell","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"2024013114245338800_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0003-2697(92)90519-D","article-title":"Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance chromatography","volume":"207","author":"Pratt","year":"1992","journal-title":"Anal Biochem"},{"key":"2024013114245338800_bib15","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","article-title":"Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease","volume":"41","author":"Blumsohm","year":"1995","journal-title":"Clin Chem"},{"key":"2024013114245338800_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.5650100318","article-title":"Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease","volume":"10","author":"Alvarez","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/000456329403100403","article-title":"Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline: Creatinine ratio in patients with Paget's disease of bone","volume":"31","author":"Kaddam","year":"1994","journal-title":"Ann Clin Biochem"},{"key":"2024013114245338800_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.5650071118","article-title":"Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases","volume":"7","author":"Ebeling","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1210\/jcem-65-1-89","article-title":"Serum osteocalcin in Paget's disease of bone: Basal concentrations and response to bisphosphonate treatment","volume":"65","author":"Papapoulos","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013114245338800_bib20","first-page":"780","article-title":"Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013114245338800_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jbmr.5650090202","article-title":"Monitoring bone resorption in early menopausal women by an immunoassays for cross-linked collagen peptides in urine","volume":"9","author":"Gertz","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF00316285","article-title":"Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover","volume":"54","author":"Rosen","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2024013114245338800_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jbmr.5650100418","article-title":"Different effects of bisphosphonate and estrogen therapy on peptide-bound bone crosslink excretion","volume":"10","author":"Garnero","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib24","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013114245338800_bib25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/39.4.635","article-title":"Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation","volume":"39","author":"Risteli","year":"1993","journal-title":"Clin Chem"},{"key":"2024013114245338800_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/jbmr.5650080515","article-title":"Immunoassay for urinary pyridinoline: The new marker of bone resorption","volume":"8","author":"Seyedin","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013114245338800_bib28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/jbmr.5650090916","article-title":"Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a private study","volume":"9","author":"Seibel","year":"1994","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.5650110817","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/11\/8\/1176\/56503543\/5650110817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/11\/8\/1176\/56503543\/5650110817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:03:04Z","timestamp":1710342184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/11\/8\/1176-1184\/7501042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8,1]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[1996,8,1]]},"published-print":{"date-parts":[[1996,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.5650110817","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1996,8,1]]},"published":{"date-parts":[[1996,8,1]]}}}